Cerus Secures Four-Year Deal with French Blood Authority for INTERCEPT System
Event summary
- Cerus Corporation signed a four-year supply agreement with Établissement Français du Sang (EFS) for the INTERCEPT Blood System, covering platelets and plasma.
- The deal includes the next-generation LED-based INT200 illumination device.
- EFS distributes approximately 330,000 units of platelets annually across 13 regional centers in France and overseas territories.
- INTERCEPT has been used in France since 2006, with nationwide adoption following a rollout in 2017.
The big picture
This agreement reinforces Cerus' position as a leader in pathogen inactivation technologies, particularly in regions with high demand for blood safety. The deal underscores the strategic importance of maintaining and expanding relationships with national blood services like EFS, which are critical to Cerus' long-term growth.
What we're watching
- Geographic Expansion
- How the INT200 will support Cerus' growth in additional territories beyond France.
- Customer Transition
- The pace at which existing customers adopt the INT200 and its impact on revenue.
- Regulatory Approvals
- Whether Cerus can secure timely regulatory approvals for the INT200 in other markets.
Our editorial coverage:
Related topics